Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Status:
Active, not recruiting
Trial end date:
2034-08-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's
Macular Degeneration.
Secondary Objective:
To assess:
- Safety
- Biological activity